BBIO: BridgeBio Pharma Inc. Stocks News on February 22, 2025

BridgeBio price target raised to $52 from $49 at Scotiabank

BBIO

TipRanks

3 hours ago

BridgeBio price target raised to $52 from $49 at Scotiabank

BBIO

Morningstar Research

19 hours ago

Analyst Report: BridgeBio Pharma, Inc.

BBIO

MT Newswires

2 days ago

Cantor Fitzgerald Adjusts BridgeBio Pharma Price Target to $95 From $70, Maintains Overweight Rating

BBIO

GuruFocus.com

2 days ago

BridgeBio Pharma Inc (BBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings

BBIO

Zacks

2 days ago

BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates

BBIO

MT Newswires

2 days ago

BridgeBio Pharma Q4 Loss Widens, Revenue Rises -- Shares Up Pre-Bell

BBIO

Associated Press Finance

2 days ago

BridgeBio Pharma: Q4 Earnings Snapshot

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

BBIO

GlobeNewswire

2 days ago

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

BridgeBio’s heart drug launch gets off to a fast start

BBIO

BioPharma Dive

2 days ago

BridgeBio’s heart drug launch gets off to a fast start

BBIO

MT Newswires

2 days ago

BridgeBio Pharma Insider Sold Shares Worth $1,140,024, According to a Recent SEC Filing

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

BBIO

GlobeNewswire

9 days ago

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

BridgeBio price target raised to $49 from $48 at Scotiabank

BBIO

TipRanks

9 days ago

BridgeBio price target raised to $49 from $48 at Scotiabank

EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment

BBIO

Pharmaceutical Technology

10 days ago

EC grants marketing authorisation to BridgeBio’s ATTR-CM treatment

BBIO

MT Newswires

11 days ago

BridgeBio Pharma Says Beyonttra Gets EU Marketing Approval for Transthyretin Amyloidosis

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

BBIO

GlobeNewswire

11 days ago

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

BBIO

BioPharma Dive

11 days ago

Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

BBIO

Insider Monkey

14 days ago

Why BridgeBio Pharma, Inc. (BBIO) Is Among the Best Healthcare Stocks To Buy According to Analysts

DHT, Evolv Technologies, and More Stocks See Action From Activist Investors

BBIO

Barrons.com

15 days ago

DHT, Evolv Technologies, and More Stocks See Action From Activist Investors

BBIO

Insider Monkey

18 days ago

Why BridgeBio Pharma Inc. (BBIO) Crashed on Monday

BBIO

MT Newswires

22 days ago

BridgeBio Pharma Insider Sold Shares Worth $2,467,761, According to a Recent SEC Filing

BBIO

MT Newswires

22 days ago

BridgeBio Pharma Insider Sold Shares Worth $21,788,650, According to a Recent SEC Filing

BBIO

Insider Monkey

24 days ago

Is BridgeBio Pharma, Inc. (BBIO) the Unstoppable Stock to Buy in 2025?

BBIO

Insider Monkey

a month ago

Why BridgeBio Pharma (BBIO) Is Skyrocketing Now

BBIO

Insider Monkey

a month ago

Why Is Andreas Halvorsen Bullish On BridgeBio Pharma, Inc. (BBIO) Now?

BridgeBio’s Neil Kumar on an underdog drug launch and wooing deal-hungry investors

BBIO

BioPharma Dive

a month ago

BridgeBio’s Neil Kumar on an underdog drug launch and wooing deal-hungry investors

BBIO

Insider Monkey

a month ago

Is BridgeBio Pharma, Inc. (BBIO) Among Tuesday’s Top Gainers?

BridgeBio Pharma Stock Earns 87 RS Rating

BBIO

Investor's Business Daily

a month ago

BridgeBio Pharma Stock Earns 87 RS Rating

BBIO

Insider Monkey

a month ago

Why BridgeBio Pharma (BBIO) Led the Monday Upsurge?

BBIO

Zacks

a month ago

Strength Seen in BridgeBio Pharma (BBIO): Can Its 16.0% Jump Turn into More Strength?

BBIO

Morningstar Research

a month ago

Analyst Report: BridgeBio Pharma, Inc.

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

BBIO

Investor's Business Daily

a month ago

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

BBIO

GlobeNewswire

a month ago

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

BBIO

GlobeNewswire

a month ago

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

BridgeBio price target raised to $50 from $45 at Evercore ISI

BBIO

TipRanks

2 months ago

BridgeBio price target raised to $50 from $45 at Evercore ISI

BBIO

MT Newswires

2 months ago

BridgeBio's Acoramidis Recommended by EU Panel for Transthyretin Amyloid Cardiomyopathy

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BBIO

GlobeNewswire

2 months ago

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BBIO

Zacks

3 months ago

Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More

BridgeBio Stock Up on FDA Approval of Cardiovascular Drug

BBIO

Zacks

3 months ago

BridgeBio Stock Up on FDA Approval of Cardiovascular Drug

FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

BBIO

Zacks

3 months ago

FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

BBIO

Morningstar Research

3 months ago

Analyst Report: BridgeBio Pharma, Inc.

BridgeBio price target raised to $45 from $42 at BofA

BBIO

TipRanks

3 months ago

BridgeBio price target raised to $45 from $42 at BofA

BBIO

MT Newswires

3 months ago

Sector Update: Health Care Stocks Rise in Monday Afternoon Trading

BBIO

MT Newswires

3 months ago

Sector Update: Health Care

BBIO

MT Newswires

3 months ago

Update: BridgeBio Pharma Shares Surge After Obtaining FDA Approval for Attruby

BBIO

MT Newswires

3 months ago

UBS Adjusts BridgeBio Pharma Price Target to $54 From $47, Maintains Buy Rating

BridgeBio Soars After Drug Gets Nod in Rare Heart Condition

BBIO

Bloomberg

3 months ago

BridgeBio Soars After Drug Gets Nod in Rare Heart Condition

BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug

BBIO

Investor's Business Daily

3 months ago

BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

BBIO

Benzinga

3 months ago

FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market

BBIO

MT Newswires

3 months ago

BridgeBio Pharma Obtains FDA Approval of Attruby

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

BBIO

Pharmaceutical Technology

3 months ago

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BBIO

GlobeNewswire

3 months ago

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

BridgeBio heart drug approved by FDA, setting up battle with Pfizer

BBIO

BioPharma Dive

3 months ago

BridgeBio heart drug approved by FDA, setting up battle with Pfizer

BBIO

Insider Monkey

3 months ago

Why Is BridgeBio Pharma, Inc. (BBIO) Among the Worst Performing Biotech Stocks in 2024?

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

BBIO

Benzinga

3 months ago

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

BBIO

Simply Wall St.

3 months ago

The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BBIO

GlobeNewswire

3 months ago

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BBIO

GlobeNewswire

3 months ago

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

BBIO

Simply Wall St.

3 months ago

BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

BBIO

Morningstar Research

3 months ago

Analyst Report: BridgeBio Pharma, Inc.

BBIO

Zacks

3 months ago

BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates

BBIO

MT Newswires

3 months ago

BridgeBio Pharma's Q3 Loss Narrows, Revenue Declines

BBIO

Associated Press Finance

3 months ago

BridgeBio Pharma: Q3 Earnings Snapshot

BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

BBIO

GlobeNewswire

3 months ago

BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management

BBIO

GlobeNewswire

4 months ago

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management

BBIO

Zacks

4 months ago

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

BBIO

GlobeNewswire

4 months ago

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

BBIO

Simply Wall St.

4 months ago

Investors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three years

BBIO

MT Newswires

4 months ago

Scotiabank Initiates BridgeBio Pharma at Sector Outperform With $44 Price Target

3 Top Stocks That Could Still Rocket Higher in 2024

BBIO

Motley Fool

5 months ago

3 Top Stocks That Could Still Rocket Higher in 2024

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

BBIO

GlobeNewswire

5 months ago

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

BBIO

MT Newswires

5 months ago

Oppenheimer Initiates BridgeBio Pharma at Perform

5 FDA decisions to watch in the fourth quarter

BBIO

BioPharma Dive

5 months ago

5 FDA decisions to watch in the fourth quarter

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

BBIO

Benzinga

5 months ago

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

BBIO

Morningstar Research

5 months ago

Analyst Report: BridgeBio Pharma, Inc.

BBIO

MT Newswires

5 months ago

BridgeBio Pharma Completes Phase 3 BBP-418 Trial Enrollment

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BBIO

GlobeNewswire

5 months ago

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

BBIO

GlobeNewswire

5 months ago

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

BBIO

MT Newswires

5 months ago

Sector Update: Health Care Stocks Steady Premarket Tuesday

BBIO

MT Newswires

5 months ago

BridgeBio Pharma Says Infigratinib Receives US FDA Breakthrough Therapy Designation

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

BBIO

GlobeNewswire

5 months ago

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly

BBIO

The Wall Street Journal

5 months ago

The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly

BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition

BBIO

Benzinga

5 months ago

BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition

BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine

BBIO

BioPharma Dive

5 months ago

BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine

BBIO

MT Newswires

5 months ago

BridgeBio Pharma Cancels Development of Congenital Adrenal Hyperplasia Treatment

BBIO

MT Newswires

5 months ago

BridgeBio Pharma Gets RMAT Designation for Gene Therapy Targeting Canavan Disease

BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program

BBIO

GlobeNewswire

5 months ago

BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program

BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

BBIO

GlobeNewswire

5 months ago

BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBIO

MT Newswires

6 months ago

Piper Sandler Initiates BridgeBio Pharma at Overweight

BBIO

MT Newswires

6 months ago

Sector Update: Health Care Stocks Softer in Afternoon Trading

Why Is BridgeBio Pharma Stock Trading Higher On Friday?

BBIO

Benzinga

6 months ago

Why Is BridgeBio Pharma Stock Trading Higher On Friday?

BBIO

MT Newswires

6 months ago

BridgeBio Pharma Reports Positive Additional Data From Phase 3 Study of Acoramidis; Shares Rise

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension

BBIO

GlobeNewswire

6 months ago

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension

Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug

BBIO

The Wall Street Journal

6 months ago

Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug

BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024

BBIO

GlobeNewswire

6 months ago

BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024

BridgeBio Pharma to Participate in September Investor Events

BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma to Participate in September Investor Events

BBIO

MT Newswires

6 months ago

BridgeBio Partners With CarDS Lab for Transthyretin Amyloid Cardiomyopathy Study

BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence

BBIO

GlobeNewswire

6 months ago

BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence

BBIO

MT Newswires

6 months ago

BridgeBio Pharma Launches GondolaBio Joint Venture

BridgeBio sends rare disease drugs to new company

BBIO

BioPharma Dive

6 months ago

Latest BridgeBio Pharma Inc. (BBIO) News on February 22, 2025

Share on Social Networks: